STEMI Clinical Trial - Super Saturated Oxygen (SSO2) Therapy in Patients

Status Not yet recruiting

Clinical Trial Summary

The goal of this clinical trial is to demonstrate the improvement in Coronary Microcirculation Dysfunction (CMD) with Super Saturated Oxygene (SSO2) therapy in patients with anterior ST-segment Elevation Myocardial Infarction (STEMI) successfully revascularized by percutaneous coronary intervention (PCI). Participants will receive SSO2 therapy for 60 minutes, which aims to overoxygenate their blood. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images.

Clinical Trial Description

Ten patients with acute anterior STEMI undergoing primary PCI will be enrolled. After successful PCI of a proximal lesion or middle left anterior descending artery (LAD), the patient will be informed and emergency consent will be obtained. SSO2 therapy will then be performed. Blood is drawn from a femoral artery sheath and circulated via a roller pump through an extracorporeal oxygenator located in a polycarbonate chamber to achieve a PaO2 of 760 to 1000 mmHg. The overoxygenated blood is then delivered to the origin of the LAD at a flow rate of 100 ml/min for 60 minutes via a dedicated catheter. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images. Then, conventional follow-up of previous STEMI will be performed by imaging and functional assessment. The primary endpoint will be analyzed using a paired Student's t test, to take into account the evolution "before/after" implementation of SSO2 therapy on CMD. The demonstration of the beneficial effect of SSO2 therapy on CMD will allow the development of a care strategy based on CMD measurement by angio-IMR. Thus, this new treatment could be reserved for patients with severe CMD for which our management arsenal is still lacking, even though we know that CMD is a major prognostic factor in STEMI patients. ;

Study Design

Related Conditions & MeSH terms

Coronary Microvascular Dysfunction
Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
STEMI

Clinical Trial Details

NCT number	NCT05790876
Study type	Interventional
Source	University Hospital, Grenoble
Contact	Gilles Barone-Rochette, MD, PhD
Phone	33476765172
Email	gbarone@chu-grenoble.fr
Status	Not yet recruiting
Phase	N/A
Start date	March 21, 2023
Completion date	June 21, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02871622` - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM	N/A
Completed	`NCT01452139` - Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)	Phase 2/Phase 3
Completed	`NCT01325116` - Delayed Educational Reminders in Acute Myocardial Infarction (MI)	N/A
Completed	`NCT01625104` - Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI	N/A
Completed	`NCT04023266` - A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI	Phase 2
Completed	`NCT02170103` - Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial	N/A
Completed	`NCT03103620` - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Not yet recruiting	`NCT05975567` - Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
Enrolling by invitation	`NCT03328156` - Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction	N/A
Completed	`NCT04017169` - No Reflow Phenomenon Incidence and Predictors
Completed	`NCT03470441` - A Study of Acute Myocardial Infarction Using FDY-5301	Phase 2
Active, not recruiting	`NCT01433627` - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX	Phase 3
Completed	`NCT01197742` - Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction	N/A
Terminated	`NCT03439150` - Resistance STEMI Study	N/A
Recruiting	`NCT03998319` - A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.	Phase 3
Not yet recruiting	`NCT05974930` - Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
Active, not recruiting	`NCT03102723` - Platelet Inhibition to Target Reperfusion Injury	Phase 2
Completed	`NCT03930589` - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size	N/A
Not yet recruiting	`NCT04912167` - The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction	Phase 3
Completed	`NCT02942550` - Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Super Saturated Oxygen (SSO2) Therapy in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Action on Coronary Microcirculation Dysfunction — IC-HOT-MICRO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms